Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.52 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.49 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.49 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141350 | 0.96 | KMT2A (0.58) | KMT2AMEN1ALDH1A1MAPTHRH3 | |
| SCHEMBL4427879 | 0.96 | KMT2A (0.57) | KMT2AMEN1ALDH1A1MAPTHRH3 | |
| SCHEMBL4123176 | 0.88 | MEN1 (0.49) | KMT2AMEN1ALDH1A1MAPTHRH3 | |
| SCHEMBL4123114 | 0.88 | HRH3 (0.56) | KMT2AMEN1ALDH1A1HRH3L3MBTL3 | |
| SCHEMBL4131556 | 0.86 | HRH3 (0.60) | KMT2AMEN1HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL4136937 | 0.86 | HRH3 (0.50) | KMT2AMEN1MAPTHRH3L3MBTL3 | |
| SCHEMBL4130409 | 0.86 | HRH3 (0.49) | KMT2AMEN1ALDH1A1MAPTHRH3 | |
| SCHEMBL3968371 | 0.84 | KMT2A (0.74) | KMT2AMEN1ALDH1A1MAPTHRH3 | |
| SCHEMBL4123123 | 0.84 | HRH3 (0.59) | ALDH1A1MAPTHRH3L3MBTL3L3MBTL1 | |
| SCHEMBL4147049 | 0.84 | L3MBTL3 (0.67) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | claimed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | claimed |
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | KMT2A 270/4885MEN1 1522/4885ALDH1A1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.